Sofiya Fedosyuk

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.

TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.

TL;DR: The protein A46 has a similar fold to other vaccinia virus anti-inflammatory proteins but uses a different dimer interface and shows a Bcl-2-like fold but with biologically relevant differences from that of A52.

TL;DR: The development of a GMP compliant process, using single-use stirred-tank bioreactors, a transgene-repressing HEK293 cell – promoter combination, and fully single- use filtration and ion exchange components, which demonstrates applicability of the process to candidate vaccines against rabies, malaria and Rift Valley fever, each based on a different adenovirus serotype.

TL;DR: In this paper, the crystal structure of Dipeptidyl peptidase 10 (DPP10) was reported and compared to that of DPP6 and DPP4, and the DPP10 dimer interface was characterized focusing on the alternative approach for designing drugs able to target protein-protein interactions.